Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

11.82 +0.33 (+2.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira. 
Via Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading. 
Via Investor's Business Daily
Where Roivant Sciences Stands With Analysts
Via Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Via Benzinga
Analyst Ratings for Roivant Sciences
Via Benzinga
8 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in  
Via Benzinga
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)  
Via Benzinga
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
From Roivant Sciences
Via GlobeNewswire
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.